US · Healthcare · Biotechnology
EPS came in at -2.85 against a street estimate of -0.57 — a miss of 400.0%.
Analysts rate Mineralys Therapeutics, Inc. Common Stock a strong buy (9 buy, 1 hold, 0 sell out of 10) with an average price target of $46.33.
| Fund | Stake |
|---|---|
| Catalys Pacific LLC | 8.94% |
| RA Capital Management, LLC | 8.70% |
| BlackRock Inc | 6.66% |
| Samsara BioCapital, LLC | 6.64% |
| FMR Inc | 5.10% |
| State Street Corp | 4.68% |
| Deerfield Management Co | 4.48% |
| Vanguard Capital Management, LLC | 3.12% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 MINERALYS THERAPEUTICS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Loss (6 months ended June 30, 2026): $280.4 million vs. $85.5 million (pr | 2026-08-11 |
| Results announced · Q3 2026 MINERALYS THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Net loss for Q2 2026: $241.1 million (vs. $43.3 million in Q2 2025) • Net loss p | 2026-08-11 |
| Company announcement · Q2 2026 MINERALYS THERAPEUTICS, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • Equity offering of 5,660,378 shares at $26.50 per share public price • Underwrite | 2026-06-03 |
| Material agreement · Q2 2026 MINERALYS THERAPEUTICS, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • Company received $100.0 million upfront cash on June 2, 2026 from a new senior se | 2026-06-03 |
| Shareholder vote results · Q2 2026 MINERALYS THERAPEUTICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held May 21, 2026 • Total shares voted on director ele | 2026-05-22 |
| Quarterly report · Q1 2026 MINERALYS THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and investments: $646.1 million as of March 31, 2026 | 2026-05-06 |
| Proxy statement · Q2 2026 MINERALYS THERAPEUTICS, INC. — PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class III directors for three-year | 2026-04-08 |
| Annual report FY2025 MINERALYS THERAPEUTICS INC. — FORM 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Company: Mineralys Therapeutics Inc. (NASDAQ: MLYS) — b | 2026-03-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mineralys Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.